Stroke is the third leading cause of death in the USA and in the developed world. The beneficial role of cholesterol reduction in decreasing stroke has been uncertain. However, recent data indicate that statin treatment in patients with a history of myocardial infarction not only reduces the risk of a second myocardial infarction, coronary heart disease, revascularization procedures and death, but also significantly reduces the risk of stroke. However, the mechanism(s) by which statins reduce stroke remain uncertain. Thus, the therapeutic armamentarium for the reduction of stroke in secondary prevention now includes cholesterol reduction with statins.
Sacco RL.Risk factors, outcomes, and stroke subtypes for ischemic stroke. Neurology1997; 49: S39-S44.
2.
Sacco RL, Kargman DE, Gu Q, Zamanillo MC.Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke1995; 26: 14-20.
3.
Silvestry FE, Tarka EA, Mohler ER.Echocardiographic and vascular ultrasound evaluation of cerebrovascular ischemic events. ACC Curr J Rev1998; 6: 79-81.
4.
Iso H, Jacobs DRJ, Wentworth D, Neaton JD, Cohen JD.Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med1989; 320: 904-910.
5.
Benfante R, Yano K, Hwang LJ, Curb JD, Kagan A, Ross W.Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke1994; 25: 814-820.
6.
Wolf PA, Kannel WB, Verter J.Current status of risk factors for stroke. Neurol Clin1983; 1: 317-343.
7.
Heyman A, Karp HR, Heyden Set al.Cerebrovascular disease in the bi-racial population of Evans County, Georgia. Stroke1971; 2: 509-518.
8.
Salonen JT, Puska P, Tuomilehto J, Homan K.Relation of blood pressure, serum lipids, and smoking to the risk of cerebral stroke. A longitudinal study in Eastern Finland. Stroke1982; 13: 327-333.
9.
Tanaka H, Ueda Y, Hayashi Met al.Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke1982; 13: 62-73.
10.
Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet1995; 346: 1647-1653.
11.
Reed D, Yano K, Kagan A.Lipids and lipoproteins as predictors of coronary heart disease, stroke, and cancer inthe Honolulu Heart Program. Am J Med1986; 80: 871-878.
12.
O’Leary DH, Polak JF, Kronmal RAet al.Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. Stroke1996; 27: 224-231.
13.
O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolf-son SK.Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med1999; 340: 14-22.
14.
Furberg CD, Adams HPJ, Applegate WBet al.Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1994; 90: 1679-1687.
15.
Crouse JR, Byington RP, Bond MGet al.Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol1995; 75: 455-459.
16.
Salonen R, Nyyssonen K, Porkkala Eet al.Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995; 92: 1758-1764.
17.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344: 1383-1389.
18.
Pedersen TR, Kjekshus J, Pyorala Ket al.Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol1998; 81: 333-335.
19.
Sacks FM, Pfeffer MA, Moye LAet al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med1996; 335: 1001-1009.
20.
Plehn JF, Davis BR, Sacks FMet al.Reduction of stroke incidence after myocardial infarction with pravastatin: the cholesterol and recurrent events (CARE) study. Circulation1999; 99: 216-223.
21.
The long-term intervention with pravastatin in ischemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med1998; 339: 1349-1357.
22.
Shepherd J, Cobbe SM, Ford Iet al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med1995; 333: 1301-1307.
23.
Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG.Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke1997; 28: 946-950.
Vaughan CJ, Murphy MB, Buckley BM.Statins do more than just lower cholesterol. Lancet1996; 348: 1079-1082.
26.
Ross R.Atherosclerosis - an inflammatory disease. N Engl J Med1999; 340: 115-126.
27.
Delanty N, Vaughan CJ.Vascular effects of statins in stroke. Stroke1997; 28: 2315-2320.
28.
Rohde E, Lee RT, Rivero Jet al.Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol1998; 18: 1765-1770.
29.
The National Institute of Neurologic Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute stroke. N Engl J Med1995; 333: 1581-1587.
30.
Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL.Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol1997; 30: 569-575.
31.
Aviram M, Rosenblat M, Bisgaier CL, Newton RS.Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis1998; 138: 271-280.
32.
O’Driscoll G, Green D, Taylor RR.Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation1997; 95: 1126-1131.
33.
Endres M, Laufs U, Huang Zet al.Stroke protection by 3-hydroxy- 3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA1998; 95: 8880-8885.
34.
Lefer A, Campbell B, Shin YK, Scalia R.Simvastatin protects the ischemic reperfused myocardium from leukocyte-endothelium interaction and neutrophil induced cardiac dysfunction. Circulation1998; 98: I-114-I-114 (Abstract).
35.
Gorelick PB, Sacco RL, Smith DBet al.Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA1999; 281: 1112-1120.
